When was Octant founded?

Octant was founded in 2017 and raised its 1st funding round 3 years after it was founded.

Where is Octant located?

Octant is headquartered in Los Angeles, United States. It is registered at Emeryville, California.

How many employees does Octant have?

As of Aug 31, 2026, the latest employee count at Octant is 68.

Is Octant a funded company?

Octant is a funded company, having raised a total of $115M across 4 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 01, 2020.

When was the latest funding round of Octant?

Octant's latest funding was a $***** Series B round on Apr 21, 2022, with participation from 5 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.32B in funding in 2026 to date.

Where does Octant rank among its competitors?

Octant ranks 26th amongst 201 active competitors, of which 76 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Relation, which secured $36.2M in Nov, 2025.

Who are the top competitors of Octant?

Octant's top competitors include Illumina, Insitro and DNAnexus. Among them, Relation secured the most recent funding round in November, 2025.

Octant - 2026 Company Profile, Team, Funding & Competitors

Octant is a series B company based in Los Angeles (United States), founded in 2017 by Ramsey Homsany and Sri Kosuri. It operates as a Provider of human cell interaction platform for drug discovery. Octant has raised $115M in funding from Andreessen Horowitz and Catalio Capital Management. The company has 201 active competitors, including 76 funded and 16 that have exited. Its top competitors include companies like Illumina, Insitro and DNAnexus.

Company Details

Provider of human cell interaction platform for drug discovery. The platform GPCR features synthetic biology, gene editing, genome engineering applications, next-generation sequencing method, and computational tools to simultaneously measure the activity of receptor pathways in human cells. These big datasets will be able to develop and apply machine learning methods to engineer small molecules which react with multiple receptors, enabling the discovery of drugs for complex diseases.

Website: www.octant.bio/
Social
Email ID: *****@octant.bio
Registered Address: Emeryville, California

Key Metrics

Founded Year

2017

Location

Los Angeles, United States

Stage

Series B

Total Funding

$115M in 4 rounds

Latest Funding Round

Series B, Apr 21, 2022, $*****

Investors

Andreessen Horowitz & 16 more

Ranked

26^th among 201 active competitors

Employee Count

68 as on Aug 31, 2026

Similar Companies

Illumina & 232 more

View Octant's full profile

Octant is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
OCTANT, INC. CIN: 821901147 , United States, Active	Dec 26, 999	-	63 (As on Dec 31, 2024)	-

Octant has raised a total funding of $115M over 4 rounds. Its first funding round was on May 01, 2020. Its latest funding round was a Series B round on Apr 21, 2022 for $*****. 5 investors participated in its latest round. Octant has 16 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Octant:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 21, 2022	8469795	Series B	5300219	5670098	5605064	5825216
Apr 01, 2021	9556329	Grant (prize money)	9483287	4901984	8037823	HHS
May 20, 2020	7654283	Series A	5980919	6774248	Andreessen Horowitz	8VC & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Octant's funding rounds and investors

The founders of Octant are Ramsey Homsany and Sri Kosuri.

Here are the details of Octant's key team members:

Ramsey Homsany: Co-Founder of Octant. They are also an angel investor in 2 startups.
Contact Info: 1 email address
Sri Kosuri: Co-Founder of Octant.
Contact Info: 1 email address

View details of Octant's Founder profiles and Board Members

Octant's employee count trend

Octant has 68 employees as of Aug 26. Here is Octant's employee count trend over the years:

Uncover Octant's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Octant include Illumina, Insitro and DNAnexus. Here is the list of Top 10 competitors of Octant, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Illumina 1993, San Diego (United States), Public	Developer of technologies for analysis of genetic variation and function	$28M	Chevron Technology Ventures, Dow Chemical Company ... & 32 others	71/100
2nd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
3rd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
4th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	Catalio Capital Management, Koch Disruptive Technologies ... & 14 others	65/100
5th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$234M	Andreessen Horowitz, Horizons Ventures & 11 others	65/100
6th	Cytel 1987, Cambridge (United States), Acquired	Provider of data analysis and statistical solutions for the life sciences industry	$2M	New Mountain Capital, Autonomy Ventures & 3 others	65/100
7th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
8th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100
9th	Arbor Biotechnologies 2016, Cambridge (United States), Series C	Provider of genomic technologies and drug discovery platform	$304M	TCG Crossover, Temasek & 27 others	64/100
10th	MGI 2016, Shenzhen (China), Series B	Provider of gene sequencing instruments, reagents, equipment, and related products	$1B	Guotai Junan Securities, CoStone Capital ... & 13 others	63/100
26th	Octant 2017, Los Angeles (United States), Series B	Provider of human cell interaction platform for drug discovery	$115M	Allen & Company, Catapult & 15 others	51/100